Tegaserod

Drug Profile

Tegaserod

Alternative Names: HTF 919; SDZ HTF 919; Zelmac; Zelnorm

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Gastrokinetics; Indoles; Irritable bowel syndrome therapies
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Constipation; Irritable bowel syndrome
  • Discontinued Dyspepsia; Gastro-oesophageal reflux

Most Recent Events

  • 27 Jul 2007 A restricted access programme has been established for tegaserod in the US for patients with Constipation with or without Irritable bowel syndrome
  • 08 Jun 2007 Withdrawn for Irritable bowel syndrome in China (PO)
  • 01 Jun 2007 Data presented at Digestive Disease Week 2007 (DDW-2007) added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top